Short Interest in Seres Therapeutics Inc (MCRB) Grows By 14.2%
Seres Therapeutics Inc (NASDAQ:MCRB) saw a large growth in short interest during the month of April. As of April 28th, there was short interest totalling 3,106,958 shares, a growth of 14.2% from the April 13th total of 2,721,263 shares. Based on an average daily volume of 167,842 shares, the days-to-cover ratio is currently 18.5 days.
Shares of Seres Therapeutics (NASDAQ:MCRB) traded down 0.2523% during trading on Monday, hitting $9.7254. 72,458 shares of the stock traded hands. The company’s 50 day moving average is $10.18 and its 200 day moving average is $10.26. The firm’s market cap is $392.81 million. Seres Therapeutics has a 52-week low of $8.05 and a 52-week high of $35.98.
Seres Therapeutics (NASDAQ:MCRB) last issued its quarterly earnings results on Thursday, May 4th. The biotechnology company reported ($0.63) EPS for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.02. The firm had revenue of $3.02 million for the quarter, compared to analysts’ expectations of $3 million. During the same quarter last year, the firm earned ($0.50) earnings per share. The business’s quarterly revenue was up 11.9% compared to the same quarter last year. On average, equities research analysts predict that Seres Therapeutics will post ($2.63) EPS for the current year.
MCRB has been the topic of several recent analyst reports. Canaccord Genuity reiterated a “buy” rating and issued a $20.00 target price on shares of Seres Therapeutics in a report on Tuesday, January 31st. FBR & Co decreased their target price on shares of Seres Therapeutics from $23.00 to $18.00 and set an “outperform” rating on the stock in a report on Wednesday, February 1st. Cantor Fitzgerald set a $16.00 target price on shares of Seres Therapeutics and gave the company a “buy” rating in a report on Tuesday, January 31st. Cowen and Company reiterated a “buy” rating on shares of Seres Therapeutics in a report on Wednesday, February 1st. Finally, Zacks Investment Research lowered shares of Seres Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, February 2nd. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $23.20.
Large investors have recently added to or reduced their stakes in the company. Ellington Management Group LLC bought a new stake in Seres Therapeutics during the fourth quarter valued at about $107,000. American International Group Inc. boosted its stake in Seres Therapeutics by 7.1% in the first quarter. American International Group Inc. now owns 10,977 shares of the biotechnology company’s stock valued at $124,000 after buying an additional 727 shares in the last quarter. Fox Run Management L.L.C. bought a new stake in Seres Therapeutics during the first quarter valued at about $136,000. Bank of Montreal Can boosted its stake in Seres Therapeutics by 33.7% in the first quarter. Bank of Montreal Can now owns 19,144 shares of the biotechnology company’s stock valued at $216,000 after buying an additional 4,829 shares in the last quarter. Finally, Citadel Advisors LLC boosted its stake in Seres Therapeutics by 74.8% in the first quarter. Citadel Advisors LLC now owns 20,662 shares of the biotechnology company’s stock valued at $233,000 after buying an additional 8,841 shares in the last quarter. 77.62% of the stock is currently owned by institutional investors and hedge funds.
About Seres Therapeutics
Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company’s drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.
Receive News & Ratings for Seres Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.